Company Search:
Advanced Search
Sponsored Links
Innate Pharma S.A. Company Snapshot
Innate Pharma S.A. operates in the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Innate Pharma S.A. with three other companies in this sector in France: Adocia SAS (2018 sales of 47.39 million Euro [US$52.42 million] of which 100% was Regenerative Medicine), Eurofins-Cerep SA (25.45 million Euro [US$28.16 million] ), and Poxel SA (74.61 million Euro [US$82.53 million] ).

Sales Analysis. Innate Pharma S.A. reported sales of 79.89 million Euro (US$88.38 million) for the year ending December of 2018. This represents an increase of 144.8% versus 2017, when the company's sales were 32.63 million Euro.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Innate Pharma S.A.
  Stock Performance Chart for Innate Pharma S.A.
  Stock Data: Recent Stock Performance:
  Current Price (12/6/2019): 5.67
(Figures in Euro)
1 Week 0.8%   13 Weeks -2.5%  
4 Weeks -5.1%   52 Weeks -28.3%  
Innate Pharma S.A. Key Data:
  Ticker: IPH Country: France
  Exchanges: PAR Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2018 Sales 79,892,000
(Year Ending Jan 2019).
Employees: 195
  Currency: Euro Market Cap: 363,023,621
  Fiscal Yr Ends: December Shares Outstanding: 64,025,330
  Share Type: Actions Ordinaires Closely Held Shares: 16,777,613
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.